Journal article
Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
The New England Journal of Medicine, Vol.363(17), pp.1648-1655
10/21/2010
DOI: 10.1056/NEJMct1000495
PMID: 20961248
Abstract
A 66-year-old man presents with a 2-week history of blurred and distorted vision in his right eye. A retinal specialist diagnoses neovascular age-related macular degeneration (AMD) and recommends treatment with ranibizumab. Foreword This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the authors' clinical recommendations. An ophthalmologist refers a 66-year-old man for consultation with a retinal specialist. The patient has had blurred and distorted vision in his right eye for the past 2 weeks. Examination reveals drusen beneath the retina in both eyes. His right eye also has a subretinal hemorrhage just temporal to the center of the macula, as well as subretinal fluid (Figure 1A). A fluorescein angiogram shows subfoveal neovascularization (Figure 1B). Optical coherence tomography reveals fluid beneath and within the layers of the retina (Figure 1C). The retinal specialist diagnoses neovascular age-related macular degeneration (AMD) and recommends intraocular injections of ranibizumab. The Clinical Problem AMD is the leading cause of blindness in the United States. All patients initially have a form of the disorder called dry AMD, characterized by the development and accumulation of drusen, which are localized deposits of extracellular material that appear as yellow spots in the retina on ophthalmoscopy. As dry AMD progresses, focal areas of atrophy of the retinal pigment epithelium appear. Wet, or neovascular, AMD then develops in some patients with established dry AMD. Wet AMD is characterized by the growth of abnormal vessels beneath the retinal pigment epithelium and between the retinal pigment epithelium and . . .
Details
- Title: Subtitle
- Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
- Creators
- James C FolkEdwin M Stone
- Resource Type
- Journal article
- Publication Details
- The New England Journal of Medicine, Vol.363(17), pp.1648-1655
- DOI
- 10.1056/NEJMct1000495
- PMID
- 20961248
- NLM abbreviation
- N Engl J Med
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- Publisher
- Massachusetts Medical Society
- Language
- English
- Date published
- 10/21/2010
- Academic Unit
- Iowa Neuroscience Institute; Ophthalmology and Visual Sciences
- Record Identifier
- 9983979939902771
Metrics
29 Record Views